GHP Specialty Care AB (publ) (GHP) today announced that the Group has won an extensive procurement process to run public health care in the United Arab Emirates (UAE). The agreement runs for five years and was officially signed today by H.E. Ahmad Juma Al Zaabi, Chairman of the Board of Directors of the Medical Office, Ministry of Presidential Affairs, in Abu Dhabi in the United Arab Emirates. The agreement will run for five years, with a possible extension of at least a further five years and comprises the managing and operating of two hospitals (which include general, emergency, women’s and children’s divisions) and a diabetes centre (currently operated by GHP). When fully operational, these will take care of more than 200,000 patients per year, of whom half are estimated to be accident and emergency cases (on a par with Sweden’s major Accident and Emergency hospitals). Pursuant to the agreement, GHP is responsible for the hospitals being run in a way that ensures quality and efficiency, so that the hospitals’ medical, operational and financial results meet the demands of the Medical Office/Ministry of Presidential Affairs. However, GHP is not taking over the costs for the day-to-day running of the hospitals. Instead, GHP will receive a management fee based on the outcome of a number of given parameters (KPIs) and delivery of a number of predefined deliverables. The agreement further stipulates that a number of the recruitments to be made will have experience of Swedish health care. “The fact that we have been chosen in this tough process is important recognition not only of GHP’s way of running quality-based health care but also of Swedish health care in general. We have been in competition with some of the most well-known and well-reputed health care organizations in the world for this prestigious contract,” says GHP’s CEO, Daniel Öhman. “The Medical Office of the Ministry of Presidential Affairs has chosen GHP in the light of their excellent high-quality management of Rashid Centre for Diabetes and Research and their good reputation and high-quality care in Sweden. We look forward to many years of successful collaboration with GHP,” says Dr Abdul Hadi Al-Ahbabi, Deputy General Manager of the Medical Office of the Ministry of Presidential Affairs. The procurement process has been rigorous and surrounded by strict confidentiality. GHP was invited last spring to take part in the procurement process due to the good results obtained at the specialist clinic RCDR, Rashid Centre for Diabetes and Research, which has been run by GHP since 2010 together with the Ministry of Health in the United Arab Emirates. During 2015 approximately 30,000 patients have been treated at RCDR, whose diabetes laboratory is ranked as one of the world leaders. The continued running of this centre is included in the new agreement. During the autumn, a delegation from the Medical Office of the Ministry of Presidential Affairs visited GHP’s clinics in Sweden and their collaboration partners. Today’s signing of the agreement concludes the procurement process. During the spring and summer in 2016, GHP will carry out comprehensive situation analyses and preparatory work to be able to take over the running of the hospitals in the third quarter of 2016. “Without giving any forecasts at present, we still want to clearly indicate that this agreement is expected to have a considerable positive impact on GHP. Revenue is decided each quarter on the basis of how well we have delivered and GHP expects to have a good operating margin from these operations,” says GHP’s Deputy CEO and CFO, Tobias Linebäck, who will be responsible for the agreement on GHP’s side. “GHP will be positively impacted by this as early as a few months into 2016, at the same time as we have had somewhat higher costs than normal during the second half of 2015 due to the procurement process and the work of winning the contract. The first half of 2016 will be affected by certain start-up costs. We will communicate more specific information shortly and in conjunction with our year-end report for 2015,” says Mr Linebäck. “GHP’s business model in the UAE differs from business operations in the Nordic region. The UAE wants to obtain leading international competence in order to deliver world-class health care services in their hospitals, and GHP’s focus is therefore on running business operations there through management contracts. In the Nordic region we see how considerable gains can be created for society by transferring selective care out of the Accident and Emergency hospitals to high -quality specialist centres. We want to own these centres ourselves so that we can invest in the development of the business operations over time and not risk losing these operations in the next procurement process. What is common to both markets is our focus on developing, together with the profession, leading-edge care while thinking along value-based lines,” says Mr Öhman. About the United Arab Emirates (UAE): The United Arab Emirates is a federation consisting of the seven emirates Abu Dhabi, Ajman, Dubai, Fujairah, Ras al-Khaimah, Sharjah and Umm al-Quwain. Abu Dhabi is the capital of the United Arab Emirates. The total population of the United Arab Emirates in 2013 was 9.2 million, with 1.4 million Emirati and 7.8 million foreigners. Public health care has been greatly expanded over the past decades and today the United Arab Emirates has a large number of highly competent specialist clinics and hospitals. Sheikh Khalifa Hospital in Ajman and Masfout and the Rashid Centre for Diabetes and Research represent a considerable part of health care in Ajman. 23 December 2015 Gothenburg, Sweden GHP Specialty Care AB (publ) Queries should be addressed to: Daniel Öhman, CEO, Tel: +46 708 55 37 07 Tobias Linebäck, CFO and Head of Investor Relations, Tel: +46 708 55 37 19 GHP is an internationally active health care provider that operates specialist clinics in a select number of diagnostic areas through the application of a business model that is unique in the health care industry, where leading doctors become partners and shareholders. Each clinic specialises in a particular patient group, and this leads to increased efficiency and higher quality. This is the cornerstone of GHP’s business philosophy – “Quality through specialisation”. GHP shares are traded on the Small Cap list of Nasdaq Stockholm under the ticker symbol “GHP”. GHP Specialty Care AB (publ) | Corp. ID No. 556757-1103 Södra Hamngatan 45 | SE-411 06 Gothenburg | Sweden Tel 46-31 712 53 00 | Fax 46-31 313 13 21 | www.ghp.se GHP Specialty Care AB is required to publish the information herein according to the Swedish Securities Market Act. This information was published on 23 December 2015 at 8:55 a.m. CET. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
GHP wins procurement process to run public health care in
Top 10 Most Recent News Articles
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation
Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
AI Drives Major Time Savings in Endoscopy Tech
AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...
Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
NARUTO Card Game Set for June 2027 Global Launch
Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...
Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias
Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...
Continue ReadingTop 5 Most Recently Viewed Articles
Investing $1000 in Lockheed Martin: A Decade of Growth
Unlocking the Power of $1000: The Journey of Lockheed Martin Lockheed Martin has excelled in the stock market, delivering impressive returns for investors who bought shares a decade ago. With a current market capitalization of $138.10 billion, this defense powerhouse has consistently outperformed the market, achieving an annualized growth rate that surpasses expectations....
Continue Reading
Fortis Financial Performance Update: Q4 Earnings Insights
Fortis Financial Performance Overview Fortis (NYSE: FTS) has recently shared its Q4 earnings results, revealing strong performance that is worth a closer look. The company's earnings announcement not only highlights its financial health but also offers insights for investors and stakeholders alike. Earnings Highlights In its latest announcement, Fortis exceeded earnings...
Continue Reading
Flowers Foods Increases Quarterly Dividend to $0.24 Per Share
Flowers Foods Declares Increased Quarterly Dividend Flowers Foods, Inc. (NYSE: FLO) has recently taken significant steps in its financial directives by announcing a quarterly dividend of $0.24 per share. This marks a commendable increase of 4.3% compared to the same quarter last year. Impressively, this is the 90th consecutive quarterly dividend paid by the company....
Continue Reading
Freeport McMoRan Adjusts Copper Sales Amid Production Setbacks
Freeport McMoRan to Delay Indonesian Copper Sales Freeport McMoRan, a significant player in the copper mining industry, has announced a postponement of its refined copper sales from Indonesia to the second quarter of 2025. This decision follows a fire incident at its new smelter, causing an unexpected delay in production. Production Challenges at Manyar Smelter The Manyar...
Continue Reading
Snowflake and Palantir: Revolutionizing AI in Data Management
Understanding the Important Deal Between Snowflake and Palantir Snowflake Inc. (NYSE: SNOW) has recently entered a significant partnership with Palantir Technologies Inc. (NYSE: PLTR), marking an important milestone in its ambitious journey towards enhancing artificial intelligence (AI) capabilities for businesses. This collaboration aims to foster enterprise AI...
Continue Reading